EE05301B1 - Meetod epotilooni analooge sisaldavate ravimvormide valmistamiseks ning nende kasutamine ravimi valmistamiseks - Google Patents

Meetod epotilooni analooge sisaldavate ravimvormide valmistamiseks ning nende kasutamine ravimi valmistamiseks

Info

Publication number
EE05301B1
EE05301B1 EEP200300320A EEP200300320A EE05301B1 EE 05301 B1 EE05301 B1 EE 05301B1 EE P200300320 A EEP200300320 A EE P200300320A EE P200300320 A EEP200300320 A EE P200300320A EE 05301 B1 EE05301 B1 EE 05301B1
Authority
EE
Estonia
Prior art keywords
medicament
manufacture
preparation
formulations containing
epothilone analogs
Prior art date
Application number
EEP200300320A
Other languages
English (en)
Estonian (et)
Inventor
Bandyopadhyay Rebanta
M. Malloy Timothy
Panaggio Andrea
Srinivas Raghavan Krishnaswamy
Amilal Varia Sailesh
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=28678063&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE05301(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Priority claimed from PCT/US2002/001813 external-priority patent/WO2002058700A1/en
Publication of EE200300320A publication Critical patent/EE200300320A/xx
Publication of EE05301B1 publication Critical patent/EE05301B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
EEP200300320A 2001-01-25 2002-01-22 Meetod epotilooni analooge sisaldavate ravimvormide valmistamiseks ning nende kasutamine ravimi valmistamiseks EE05301B1 (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26422801P 2001-01-25 2001-01-25
US29000801P 2001-05-11 2001-05-11
PCT/US2002/001813 WO2002058700A1 (en) 2001-01-25 2002-01-22 Methods of administering epothilone analogs for the treatment of cancer

Publications (2)

Publication Number Publication Date
EE200300320A EE200300320A (et) 2003-10-15
EE05301B1 true EE05301B1 (et) 2010-06-15

Family

ID=28678063

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300320A EE05301B1 (et) 2001-01-25 2002-01-22 Meetod epotilooni analooge sisaldavate ravimvormide valmistamiseks ning nende kasutamine ravimi valmistamiseks

Country Status (24)

Country Link
US (1) US6670384B2 (cs)
EP (2) EP1353668B1 (cs)
KR (1) KR100851719B1 (cs)
CN (1) CN100341505C (cs)
AR (1) AR032409A1 (cs)
AT (1) ATE389401T1 (cs)
BG (1) BG66494B1 (cs)
BR (1) BRPI0206509B8 (cs)
CY (1) CY1108114T1 (cs)
CZ (1) CZ20032021A3 (cs)
DE (1) DE60225666T2 (cs)
DK (1) DK1353668T3 (cs)
EE (1) EE05301B1 (cs)
ES (1) ES2304240T3 (cs)
HU (1) HU229349B1 (cs)
IS (1) IS2865B (cs)
NO (1) NO20130070L (cs)
NZ (1) NZ526870A (cs)
PE (1) PE20020734A1 (cs)
PT (1) PT1353668E (cs)
SK (1) SK288098B6 (cs)
TW (1) TWI342211B (cs)
UY (1) UY27137A1 (cs)
YU (1) YU58203A (cs)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU756699B2 (en) 1996-12-03 2003-01-23 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6204388B1 (en) * 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6867305B2 (en) 1996-12-03 2005-03-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
UA75365C2 (en) 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
SK8552003A3 (en) * 2001-01-25 2004-06-08 Bristol Myers Squibb Co Parenteral formulation containing epothilone analogs
JP2004522774A (ja) 2001-02-20 2004-07-29 ブリストル−マイヤーズ　スクイブ　カンパニー エポチロン誘導体を用いる耐性腫瘍の治療
ES2384789T3 (es) * 2001-03-14 2012-07-12 Bristol-Myers Squibb Company Combinación de un análogo de epotilona y agentes quimioterapéuticos para el tratamiento de enfermedades proliferativas
WO2003077903A1 (en) * 2002-03-12 2003-09-25 Bristol-Myers Squibb Company C12-cyano epothilone derivatives
TW200400191A (en) * 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
PT1767535E (pt) 2002-08-23 2010-02-24 Sloan Kettering Inst Cancer Síntese de epotilonas, respectivos intermediários, análogos e suas utilizações
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
JP2007504259A (ja) * 2003-09-02 2007-03-01 ノバルティス アクチエンゲゼルシャフト エポチロンでの癌処置
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
US20090004277A1 (en) * 2004-05-18 2009-01-01 Franchini Miriam K Nanoparticle dispersion containing lactam compound
WO2006055742A1 (en) * 2004-11-18 2006-05-26 Bristol-Myers Squibb Company Enteric coated bead comprising epothilone or epothilone analog, and preparation and administration thereof
ATE397442T1 (de) * 2004-11-18 2008-06-15 Bristol Myers Squibb Co Magensaftresistent beschichtetes pellet mit ixabepilon
EP1674098A1 (en) * 2004-12-23 2006-06-28 Schering Aktiengesellschaft Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water
AU2006336468B2 (en) 2005-02-11 2012-04-12 University Of Southern California Method of expressing proteins with disulfide bridges
CN1870631B (zh) * 2005-11-11 2010-04-14 华为技术有限公司 媒体网关的门控方法
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
US8008256B2 (en) 2006-05-01 2011-08-30 University Of Southern California Combination therapy for treatment of cancer
WO2010056901A2 (en) 2008-11-13 2010-05-20 University Of Southern California Method of expressing proteins with disulfide bridges with enhanced yields and activity
US8263581B2 (en) * 2009-07-03 2012-09-11 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
US8513259B2 (en) 2009-07-03 2013-08-20 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
AU2011255647A1 (en) 2010-05-18 2012-11-15 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other diseases
JP2014516075A (ja) 2011-06-06 2014-07-07 シェブロン フィリップス ケミカル カンパニー エルピー 癌治療のためのメタロセン化合物の使用
PL401116A1 (pl) * 2012-10-09 2014-04-14 Ryszka Florian Farmaceutyczny Zakład Naukowo-Produkcyjny Biochefa Kompozycja dodawana do płynów infuzyjnych
CN107041886A (zh) * 2016-02-06 2017-08-15 北京华昊中天生物技术有限公司 脱环氧埃坡霉素衍生物制剂、制备及其治疗肿瘤的应用
WO2021142202A1 (en) 2020-01-10 2021-07-15 R-Pharm Us Operating Llc Compositions of ixabepilone
AU2021337086B2 (en) * 2020-09-02 2024-02-29 Beijing Biostar Pharmaceuticals Co., Ltd. Solid oral formulation of utidelone

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4138042C2 (de) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
EP0873341B1 (de) 1995-11-17 2003-09-10 Gesellschaft für biotechnologische Forschung mbH (GBF) Epothilonderivate, herstellung und verwendung
DE19542986A1 (de) 1995-11-17 1997-05-22 Biotechnolog Forschung Gmbh Epothilon-Derivate und deren Verwendung
DE19639456A1 (de) 1996-09-25 1998-03-26 Biotechnolog Forschung Gmbh Epothilon-Derivate, Herstellung und Mittel
US6011029A (en) 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
EP0923583A1 (de) 1996-08-30 1999-06-23 Novartis AG Verfahren zur herstellung von epothilonen und zwischenprodukte innerhalb des verfahrens
DE19645361A1 (de) 1996-08-30 1998-04-30 Ciba Geigy Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B, Teil II
DE19645362A1 (de) 1996-10-28 1998-04-30 Ciba Geigy Ag Verfahren zur Herstellung von Epothilon A und B und Derivaten
DE59711647D1 (de) 1996-11-18 2004-06-24 Biotechnolog Forschung Gmbh Epothilon d, dessen herstellung und dessen verwendung als cytostatisches mittel bzw. als pflanzenschutzmittel
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
AU756699B2 (en) * 1996-12-03 2003-01-23 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6380394B1 (en) 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
DE19701758A1 (de) 1997-01-20 1998-07-23 Wessjohann Ludgar A Dr Epothilone-Synthesebausteine
AU736062B2 (en) 1997-02-25 2001-07-26 Gesellschaft Fur Biotechnologische Forschung Mbh Epothilones which are modified in the side chain
DE19713970B4 (de) 1997-04-04 2006-08-31 R&D-Biopharmaceuticals Gmbh Epothilone-Synthesebausteine II - Prenylderivate
WO1998047891A1 (de) 1997-04-18 1998-10-29 Studiengesellschaft Kohle Mbh Selektive olefinmetathese von bi- oder polyfunktionellen substraten in komprimiertem kohlendioxid als reaktionsmedium
DE19720312A1 (de) 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
DE19821954A1 (de) 1997-05-15 1998-11-19 Biotechnolog Forschung Gmbh Verfahren zur Herstellung eines Epothilon-Derivats
GB9801231D0 (en) 1997-06-05 1998-03-18 Merck & Co Inc A method of treating cancer
DE19726627A1 (de) 1997-06-17 1998-12-24 Schering Ag Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US6384230B1 (en) 1997-07-16 2002-05-07 Schering Aktiengesellschaft Thiazole derivatives, method for their production and use
US7407975B2 (en) 1997-08-09 2008-08-05 Bayer Schering Pharma Ag Epothilone derivatives, method for producing same and their pharmaceutical use
US6040321A (en) 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
WO1999039694A2 (en) 1998-02-05 1999-08-12 Novartis Ag Compositions containing organic compounds
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
JP2002504540A (ja) 1998-02-25 2002-02-12 スローン−ケッタリング インスティトゥート フォア キャンサー リサーチ エポチロンの合成、その中間体およびそのアナログ
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6399638B1 (en) 1998-04-21 2002-06-04 Bristol-Myers Squibb Company 12,13-modified epothilone derivatives
AU5036999A (en) 1998-06-30 2000-01-17 Schering Aktiengesellschaft Epothilon derivatives, their preparation process, intermediate products and their pharmaceutical use
AU768220B2 (en) 1998-11-20 2003-12-04 Kosan Biosciences, Inc. Recombinant methods and materials for producing epothilone and epothilone derivatives
JP2002533346A (ja) 1998-12-22 2002-10-08 ノバルティス アクチエンゲゼルシャフト エポシロン誘導体およびそれらの抗腫瘍剤としての使用
EE200100431A (et) 1999-02-18 2002-12-16 Schering Aktiengesellschaft 16-halogenoepotilooni derivaadid, nende valmistamismeetod ja farmatseutiline kasutamine
US6211412B1 (en) 1999-03-29 2001-04-03 The University Of Kansas Synthesis of epothilones
AR023792A1 (es) 1999-04-30 2002-09-04 Bayer Schering Pharma Ag Derivados 6-alquenilo- y 6-alquinilo-epotilona, los procedimientos para prepararlos y su empleo en productos farmaceuticos
AU2001266583A1 (en) * 2000-05-26 2001-12-11 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same

Also Published As

Publication number Publication date
HK1116339A1 (en) 2008-12-19
KR20040048874A (ko) 2004-06-10
YU58203A (sh) 2006-08-17
EP1353668B1 (en) 2008-03-19
IS2865B (is) 2014-02-15
BG108112A (bg) 2004-11-30
AR032409A1 (es) 2003-11-05
TWI342211B (en) 2011-05-21
ES2304240T3 (es) 2008-10-01
EP1353668A1 (en) 2003-10-22
EP1938821A3 (en) 2009-02-18
NO20130070L (no) 2003-09-04
DE60225666T2 (de) 2009-04-16
BRPI0206509B8 (pt) 2021-05-25
PE20020734A1 (es) 2002-08-17
HUP0302726A2 (hu) 2003-11-28
NZ526870A (en) 2005-11-25
EP1938821B1 (en) 2016-03-30
HUP0302726A3 (en) 2007-08-28
PT1353668E (pt) 2008-06-30
ATE389401T1 (de) 2008-04-15
US6670384B2 (en) 2003-12-30
SK8562003A3 (en) 2004-07-07
KR100851719B1 (ko) 2008-08-11
BRPI0206509B1 (pt) 2018-10-02
DK1353668T3 (da) 2008-06-30
BG66494B1 (bg) 2015-06-30
HK1065946A1 (en) 2005-03-11
EP1938821A2 (en) 2008-07-02
CN1496258A (zh) 2004-05-12
BR0206509A (pt) 2004-09-08
CY1108114T1 (el) 2014-02-12
CZ20032021A3 (cs) 2004-05-12
SK288098B6 (sk) 2013-07-02
BRPI0206509A8 (pt) 2017-09-19
US20020169190A1 (en) 2002-11-14
IS6891A (is) 2003-07-24
HU229349B1 (en) 2013-11-28
DE60225666D1 (de) 2008-04-30
CN100341505C (zh) 2007-10-10
EE200300320A (et) 2003-10-15
UY27137A1 (es) 2002-08-30

Similar Documents

Publication Publication Date Title
EE05301B1 (et) Meetod epotilooni analooge sisaldavate ravimvormide valmistamiseks ning nende kasutamine ravimi valmistamiseks
EE200300151A (et) Ravimitena kasutatavad antikolinergikumid ning meetodid nende valmistamiseks
HUP0400203A3 (en) Use of combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases, for preparation of pharmaceutical compositions
DE60224111D1 (de) Bausatz zur Herstellung einer Verabreichungsform zur Abgabe einer bioaktiven Substanz
NO324227B1 (no) Cyclopropyl-kondenserte pyrrolidin-baserte forbindelser, farmasoytiske blandinger og kombinasjoner inneholdende slike samt anvendelse av slike for fremstilling av medikamenter for behandling av sykdommer
HUP0303078A3 (en) Cyclic peptidies process for their preparation pharmaceutical compositions containing them and their use
DE60239648D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von Asthma
AR028426A1 (es) Una composicion farmaceutica y procedimiento de tratamiento de enfermedades de disfunsion cognitiva en un mamifero
HRP20020893A2 (en) Formulations containing a glucocorticoid drug for the treatment of bronchopulmonary diseases
FI20000780L (fi) Peroraalinen lääkemuoto lääkeaineen hallituksi vapauttamiseksi
EP1359927A4 (en) PHYTOPHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING IMMUNOLOGICAL DISEASES
HUP0401325A3 (en) Isoxazolopyridinones useful in the treatment of parkinson's disease, process for their preparation and pharmaceutical compositions containing the compounds
AU2002231811A1 (en) Use of flumazenil to produce a medicament for the treatment of cocaine dependency
HUP0303055A3 (en) Polymorphs of zaleplon and methods for the preparation thereof and pharmaceutical compositions containing them
HUP0204391A3 (en) The use of mirtazapine for the preparation of pharmaceutical composition suitable for the treatment of sleep disorders
IL170518A (en) Liquid oral dosage formulations comprising 5-methyl-2-(2'-chloro-6'-fluoroanilino) phenylacetic acid, methods for preparing them and use thereof for the manufacture of medicaments
DE60114668D1 (de) Prozess zur Herstellung des Anti-Migräne Wirkstoffs Eletriptan
IL160886A0 (en) Nicotine containing pharmaceutical formulations and use thereof
IL172213A0 (en) Compounds useful in the therapy of alzheimer's disease and formulations containing them
EE04941B1 (et) Ravimid skisofreenia ennetamiseks ja raviks ning nende valmistamine
IL158587A0 (en) Novel 5-thio-ss-d-xylopyranoside derivatives, preparation method thereof, pharmaceutical compositions containing same and the therapeutic use thereof
PL357466A1 (en) Optically active 2-aminotetralin derivatives, the processes for the preparation thereof and the therapeutical use of pharmaceutical compositions containing them
ITMI20011284A0 (it) Composizione farmaceutica per il trattamento dell'iperfosfatemia
GB0024517D0 (en) Use of medicaments
UA5369S (uk) Упаковка для медичного препарату «настойка женьшеню»

Legal Events

Date Code Title Description
HD1A Correction of address
KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20170122